Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzthiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 9/20 | 0.38 |
| ▸ | CA2 | P00918 | 9/20 | 0.38 |
| ▸ | CA12 | O43570 | 8/20 | 0.37 |
| ▸ | CA6 | P23280 | 8/20 | 0.37 |
| ▸ | CA7 | P43166 | 8/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzthiazide SCHEMBL2452168 | 0.89 | ALDH1A1 (0.51) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL2449654 | 0.89 | ALDH1A1 (0.51) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL198231 | 0.89 | ALDH1A1 (0.52) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL26257 | 0.87 | ALDH1A1 (0.63) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL2376967 | 0.86 | ALDH1A1 (0.58) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL386199 | 0.86 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL1276519 | 0.86 | ALDH1A1 (0.60) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL7102453 | 0.86 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL345215 | 0.86 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL7217920 | 0.86 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024008889-A1 | RECOMBINANT HOST CELLS PRODUCING IRONES AND USES THEREOF | MUSEUM NATIONAL D'HISTOIRE NATURELLE (FR) | 2024-01-11 | — | — | WO | disclosed |
| EP-4303308-A1 | RECOMBINANT HOST CELLS PRODUCING IRONES AND USES THEREOF | MUSEUM NATIONAL D'HISTOIRE NATURELLE (FR) | 2024-01-10 | — | — | EP | disclosed |
| US-11845964-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11390896-B2 | Method for producing L-methionine using a bacterium of the genus Pantoea | AJINOMOTO CO., INC. (JP) | 2022-07-19 | — | — | US | disclosed |
| EP-3940067-A1 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | Synlogic Operating Company, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3856918-A1 | METHOD FOR PRODUCING L-METHIONINE USING A BACTERIUM | AJINOMOTO CO., INC. (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3227440-B1 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC OPERATING CO INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-11060073-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | SYNLOGIC OPERATING COMPANY, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210207182-A1 | METHOD FOR PRODUCING L-METHIONINE USING A BACTERIUM | AJINOMOTO CO., INC. (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20210180033-A1 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC OPERATING COMPANY, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-1526179-B1 | Method for producing l-amino acid using bacteria belonging to the genus escherichia | AJINOMOTO KK (JP) | 2007-05-02 | — | — | EP | disclosed |
| EP-1747269-A2 | RECOMBINANT ENZYME WITH ALTERED FEEDBACK SENSITIVITY | Metabolic Explorer (FR) | 2007-01-31 | — | — | EP | disclosed |
| WO-2006082254-A2 | MICROORGANISMS COMPRISING ENZYMES EXPRESSED WITH LOW GAMMA-ELIMINATION ACTIVITY | METABOLIC EXPLORER (FR) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082252-A2 | METHOD FOR THE ENZYMATIC PRODUCTION OF ALPHA-KETOBUTYRATE | METABOLIC EXPLORER (FR) | 2006-08-10 | — | — | WO | disclosed |
| EP-1239041-B1 | Method for producing L-amino acid using bacteria belonging to the genus Escherichia | AJINOMOTO KK (JP) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005108561-A2 | RECOMBINANT ENZYME WITH ALTERED FEEDBACK SENSITIVITY | METABOLIC EXPLORER (FR) | 2005-11-17 | — | — | WO | disclosed |
| US-20050239175-A1 | Method for producing L-amino acid using bacteria belonging to the genus Escherichia | AJINOMOTO CO., INC. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1526179-A1 | Method for producing l-amino acid using bacteria belonging to the genus escherichia | Ajinomoto Co., Inc. (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-1526181-A1 | Method for producing l-amino acid using bacteria belonging to the genus escherichia | Ajinomoto Co., Inc. (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-1239041-A2 | Method for producing L-amino acid using bacteria belonging to the genus Escherichia | Ajinomoto Co., Inc. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845964-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | ASS1, AGXT, OAT | ALDH1A1 1080/4885KDM4E 3926/4885MEN1 787/4885 |
| US-11060073-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | ASS1, AGXT, OAT | ALDH1A1 1080/4885KDM4E 3926/4885MEN1 787/4885 |
| US-20210180033-A1 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | ASS1, AGXT, OAT | ALDH1A1 1080/4885KDM4E 3926/4885MEN1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.